Pfizer Global Research and Development, La Jolla Laboratories, 10724 Science Center Drive, San Diego, CA 92121, USA.
Mol Cancer Res. 2010 May;8(5):717-28. doi: 10.1158/1541-7786.MCR-09-0291. Epub 2010 Apr 20.
We investigated the role of Nek6, a member of the NIMA-related serine/threonine kinase family, in tumorigenesis. Transcript, protein, and kinase activity levels of Nek6 were highly elevated in the malignant tumors and human cancer cell lines compared with normal tissue and fibroblast cells. Expression of exogenous wild-type Nek6 increased anchorage-independent growth of a variety of human cancer cell lines, whereas overexpression of the kinase-dead Nek6 and RNAi knockdown of endogenous Nek6 suppressed cancer cell transformation and induced apoptosis. Additionally, in in vivo xenograft nude mouse model, knockdown of Nek6 in HeLa cells resulted in reduction of tumor size relative to control siRNA tumors. Most importantly, knocking down endogenous Nek6 levels or exogenous expression of the kinase-dead form did not inhibit cell proliferation, nor did it induce apoptosis in normal fibroblast cells. Taken together, our data indicate a pivotal role for Nek6 in tumorigenesis and establish Nek6 as a potential target for treatment of a variety of human cancers.
我们研究了 Nek6 在肿瘤发生中的作用。与正常组织和成纤维细胞相比,NIMA 相关丝氨酸/苏氨酸激酶家族的成员 Nek6 的转录本、蛋白质和激酶活性水平在恶性肿瘤和人类癌细胞系中显著升高。外源性野生型 Nek6 的表达增加了多种人类癌细胞系的无锚定生长,而激酶失活型 Nek6 的过表达和内源性 Nek6 的 RNAi 敲低抑制了癌细胞的转化并诱导了细胞凋亡。此外,在体内异种移植裸鼠模型中,与对照 siRNA 肿瘤相比,HeLa 细胞中 Nek6 的敲低导致肿瘤体积减小。最重要的是,敲低内源性 Nek6 水平或外源性表达激酶失活形式既不会抑制正常成纤维细胞的细胞增殖,也不会诱导细胞凋亡。总之,我们的数据表明 Nek6 在肿瘤发生中起关键作用,并将 Nek6 确立为治疗多种人类癌症的潜在靶点。